Absorb IV Randomized Controlled Trial



Status:Active, not recruiting
Conditions:Peripheral Vascular Disease, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:11/3/2018
Start Date:July 2014
End Date:April 2022

Use our guide to learn which trials are right for you!

A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind,
multi-center study, registering approximately 2610 subjects from approximately 140 sites in
the United States and outside the United States. ABSORB IV is a continuation of ABSORB III
(NCT01751906) trial which are maintained under one protocol because both trial designs are
related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV
primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.

The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the
safety and effectiveness as well as the potential short and long-term benefits of Abbott
Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
(once commercially available), as compared to the commercially approved, control stent
XIENCE.

ABSORB IV:

A. Primary Objective:

- To evaluate 30-day clinical outcomes of the Absorb BVS compared to XIENCE in the
treatment of subjects with ischemic heart disease caused by up to three de novo native
coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
lesions per epicardial vessel.

- To evaluate long-term clinical outcomes of Absorb BVS compared to XIENCE in the
treatment of subjects with ischemic heart disease caused by up to three denovo native
coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
lesions per epicardial vessel.

B. Secondary Objectives:

- To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the
treatment of subjects with ischemic heart disease caused by up to three de novo native
coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two
lesions per epicardial vessel.

- To evaluate the incidence of angina occurring within 1 year, with treatment of Absorb
BVS compared to XIENCE.

The enrollment of the 2610 subjects in ABSORB IV will start after enrollment completion of
the 2000 primary analysis subjects in ABSORB III. All registered subjects will have clinical
follow-up at 30, 90, 180, 270 days and 1, 2, 3, 4, 5, 6 and 7 years.

Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or
9 years and/or 10 years via telephone contact/office visit if it is necessary as determined
by the Sponsor.

In addition, all 2610 subjects in ABSORB IV will complete patient-reported outcome (PRO)
self-administered questionnaires at baseline, 30 days,180 days, 1 year, 3 years and 5 years.

General Inclusion Criteria:

1. Subject must be at least 18 years of age.

2. Subject or a legally authorized representative must provide written Informed Consent
prior to any study related procedure, per site requirements.

3. Subject must have evidence of myocardial ischemia (e.g., silent ischemia, stable or
unstable angina, non-ST-segment elevation MI (NSTEMI), OR recent ST-segment elevation
MI (STEMI). Patients with stable coronary syndromes can be enrolled any time after
symptom onset if eligibility criteria are otherwise met. Patients with acute coronary
syndrome can be enrolled under the following conditions:

1. Unstable angina or NSTEMI within 2 weeks of the index procedure.

2. STEMI > 72 hours ≤ 2 weeks prior to the index procedure.

Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring > 2 weeks of the
index procedure can be included in the trial but should be categorized based on their
current angina class.

4. Subjects must be suitable for PCI. Subjects with stable angina or silent ischemia and
< 70% diameter stenosis must have objective signs of ischemia as determined by one of
the following: abnormal stress echocardiogram, nuclear scan, electrocardiogram (ECG),
positron emission tomography (PET), magnetic resonance imaging (MRI), and/or
fractional flow reserve (FFR).

(Note: subject with silent ischemia must have a prior history of typical angina,
angina-equivalent symptoms, or atypical angina within the past year to be included in
the trial.)

5. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
surgery.

6. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
following the index procedure. For a female subject of childbearing potential a
pregnancy test must be performed with negative results known within 7 days prior to
the index procedure per site standard.

7. Female subject is not breast-feeding at the time of the screening visit and will not
be breast-feeding for at least 1 year following the index procedure.

8. Subject agrees to not participate in any other investigational or invasive clinical
study for a period of 5 years following the index procedure.

Angiographic Inclusion Criteria:

Treatment of up to three de novo lesions in a maximum of two epicardial vessels, with a
maximum of two lesions per epicardial vessel. If only a single lesion is to be treated, it
must be a target lesion. Up to one non-target lesion can be treated. Non-target lesion
treatment can occur only in a non-target vessel.

If there are two target lesions within the same epicardial vessel, the two target lesions
must be at least 15 mm apart per visual estimation; otherwise this is considered as a
single target lesion for lesion (and stent) length determination and must be treated with a
single study device.

1. Target lesion(s) must be located in a native coronary artery with a visually estimated
or quantitatively assessed %DS of ≥50% and < 100%, with a thrombolysis in myocardial
infarction (TIMI) flow of ≥ 1, and one of the following: stenosis ≥ 70%, an abnormal
functional test (e.g., fractional flow reserve ≤0.80 AND/OR a positive stress test), or
presentation with an acute coronary syndrome (unstable angina or NSTEMI within 2 weeks of
index procedure, or STEMI >72 hours but ≤ 2 weeks prior to the index procedure).

1. Target lesion(s) must be located in a native coronary artery with reference vessel
diameter (RVD) by visual estimation of ≥ 2.50 mm and ≤ 3.75 mm.

2. Target lesion(s) must be located in a native coronary artery with length by visual
estimation of ≤ 24 mm.

Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring > 2 weeks of the
index procedure can be included in the trial but should be categorized based on their
current angina class.

Note: To exclude enrollment of excessively small vessels, if the operator believes that
based on visual angiographic assessments, the distal reference vessel diameter is ≤ 2.75 mm
such that the plan is to implant a 2.5 mm device (stent or scaffold) in a target lesion, it
is strongly recommended that either on-line QCA or intravascular imaging (ultrasound or
optical coherence tomography) is used and demonstrates that the measured distal RVD for
this target lesion is ≥ 2.50 mm (by at least one of these imaging modalities). This
measurement may be performed before or after pre-dilatation, but before randomization. If
the distal RVD measures <2.5 mm, that lesion IS NOT ELIGIBLE for randomization. Such a
lesion may be treated as a non-target lesion.

General Exclusion Criteria:

1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or a P2Y12
receptor inhibitor is planned within 12 months after the procedure.

2. Subject has known hypersensitivity or contraindication to device material and its
degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
adequately pre-medicated.

3. Subject has known allergic reaction, hypersensitivity or contraindication to any of
the following: aspirin; or clopidogrel and prasugrel and ticagrelor; or heparin and
bivalirudin, and therefore cannot be adequately treated with study medications.

4. Subject had an acute STEMI (appropriate clinical syndrome with ≥1 mm of ST-segment
elevation in ≥2 contiguous leads) within 72 hours of the index procedure.

5. Subject has a cardiac arrhythmia identified at the time of screening for which at
least one of the following criteria is met:

1. Subject requires coumadin or any other agent for chronic oral anticoagulation.

2. Subject is likely to become hemodynamically unstable due to their arrhythmia.

3. Subject has poor survival prognosis due to their arrhythmia.

6. Subject has a left ventricular ejection fraction (LVEF) < 30% assessed by any
quantitative method, including but not limited to echocardiography, MRI,
multiple-gated acquisition (MUGA) scan, contrast left ventriculography, PET scan, etc.
LVEF may be obtained within 6 months prior to the procedure for subjects with stable
CAD. For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed
within 1 week of the index procedure and after ACS presentation, which may include
contrast left ventriculography during the index procedure but prior to randomization
in order to confirm the subject's eligibility.

7. Subject has undergone prior PCI within the target vessel during the last 12 months.
Prior PCI within the non-target vessel or any peripheral intervention is acceptable if
performed anytime >30 days before the index procedure, or between a minimum of 24
hours and 30 days before the index procedure if successful and uncomplicated.

8. Subject requires future staged PCI of any lesion other than a target lesion identified
at the time of index procedure; or subject requires future peripheral vascular
interventions < 30 days after the index procedure.

9. Subject has received any solid organ transplants or is on a waiting list for any solid
organ transplants.

10. At the time of screening, the subject has a malignancy that is not in remission.

11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
not included as immunosuppressant therapy.

12. Subject has previously received or is scheduled to receive radiotherapy to a coronary
artery (vascular brachytherapy), or the chest/mediastinum.

13. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
dabigatran, apixaban, rivaroxaban, edoxaban or any other related agent for any
reason).

14. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.

15. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
Child-Pugh ≥ Class B.

16. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
(GFR) < 30 ml/min/1.73m2 or dialysis at the time of screening.

17. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
or coagulopathy; has had a significant gastrointestinal or significant urinary bleed
within the past six months.

18. Subject has had a cerebrovascular accident or transient ischemic neurological attack
(TIA) within the past six months, or any prior intracranial bleed, or any permanent
neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous
malformation, etc.).

19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
insertion. Note: femoral arterial disease does not exclude the patient if radial
access may be used.

20. Subject has a life expectancy <5 years for any non-cardiac or cardiac cause.

21. Subject is in the opinion of the Investigator or designee, unable to comply with the
requirements of the study protocol or is unsuitable for the study for any reason. This
includes completion of Patient Reported Outcome instruments.

22. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint.

23. Subject is part of a vulnerable population who, in the judgment of the investigator,
is unable to give Informed Consent for reasons of incapacity, immaturity, adverse
personal circumstances or lack of autonomy. This may include: Individuals with a
mental disability, persons in nursing homes, children, impoverished persons, persons
in emergency situations, homeless persons, nomads, refugees, and those incapable of
giving informed consent. Vulnerable populations also may include members of a group
with a hierarchical structure such as university students, subordinate hospital and
laboratory personnel, employees of the Sponsor, members of the armed forces, and
persons kept in detention.

Angiographic Exclusion Criteria:

All exclusion criteria apply to the target lesion(s) or target vessel(s).

1. Unsuccessful pre-dilatation, defined as the presence of one or more of the following
(note: successful pre-dilatation of at least one target lesion is required prior to
randomization):

1. Residual %diameter stenosis (DS) after pre-dilatation is ≥ 40% (per visual
estimation). Note: achieving a %DS ≤ 20% prior to randomization is strongly
recommended.

2. TIMI flow grade <3 (per visual estimation).

3. Any angiographic complication (e.g. distal embolization, side branch closure).

4. Any dissection NHLBI grade D-F.

5. Any chest pain lasting > 5 minutes.

6. Any ST-segment depression or elevation lasting > 5 minutes.

2. Lesion is located in left main or there is a ≥30% diameter stenosis in the left main
(unless the left main lesion is a protected left main (i.e. a patent bypass graft to
the LAD and/or LCX arteries is present), and there is no intention to treat the
protected left main lesion).

3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

4. Lesion located within 3 mm of the origin of the left anterior descending artery (LAD)
or left circumflex artery (LCX).

5. Lesion involving a bifurcation with a:

1. side branch ≥ 2 mm in diameter, or

2. side branch with either an ostial or non-ostial lesion with diameter stenosis
>50%, or

3. side branch requiring dilatation

6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
XIENCE stent:

1. Extreme angulation (≥ 90°) proximal to or within the target lesion.

2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.

3. Moderate or heavy calcification proximal to or within the target lesion. If
intravascular ultrasound (IVUS) used, subject must be excluded if calcium arc in
the vessel prior to the lesion or within the lesion is ≥ 180°.

7. Lesion or vessel involves a myocardial bridge.

8. Vessel has been previously treated with a stent and the target lesion is within 5 mm
proximal or distal to a previously stented lesion.

9. Target lesion located within an arterial or saphenous vein graft or distal to any
arterial or saphenous vein graft.
We found this trial at
128
sites
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Peter Ver Lee
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Massoud Leesar
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Principal Investigator: Anna Bortnick
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
Principal Investigator: Hadley Wilson
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Joshua Purow
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
1 Shircliff Way
Jacksonville, Florida 32204
Principal Investigator: Samer Garas
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Mamoo Nakamura
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Mark Glazer
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Principal Investigator: Annapoorna Kini
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
22 Bramhall St
Portland, Maine 04102
(207) 662-0111
Principal Investigator: Thomas Ryan
Maine Medical Center One of the country's consistently highest rated hospitals is right in your...
?
mi
from
Portland, ME
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Barry Sharaf
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
Sacramento, California 95814
Principal Investigator: Reginald Low
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Fadi Matar
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Joaqin Martinez-Arraras
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Anderson, South Carolina 29621
Principal Investigator: Brent McLaurin
?
mi
from
Anderson, SC
Click here to add this to my saved trials
Ann Arbor, Michigan 48197
Principal Investigator: Zakir Sahul
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Habib Samady
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30309
Principal Investigator: David Kandzari
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Principal Investigator: Habib Samady
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Osvaldo Gigliotti
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland
Principal Investigator: John Wang
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bay City, Michigan 48708
Principal Investigator: Daniel Lee
?
mi
from
Bay City, MI
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Alice Jacobs
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02241
Principal Investigator: Ron Waksman
?
mi
from
Boston, MA
Click here to add this to my saved trials
77 Morris Avenue
Bryn Mawr, Pennsylvania 19010
Principal Investigator: Antonis Pratsos
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Camden, New Jersey 08103
Principal Investigator: Vijayendra Verma
?
mi
from
Camden, NJ
Click here to add this to my saved trials
1 Cooper Plaza
Camden, New Jersey 08103
(856) 342-2000
Principal Investigator: Georges Kaddissi
Cooper University Hospital Cooper University Health Care, the clinical campus of Cooper Medical School of...
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Camp Hill, Pennsylvania 17011
Principal Investigator: Rajesh Dave
?
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Canton, Ohio 44710
Principal Investigator: John Paulowski
?
mi
from
Canton, OH
Click here to add this to my saved trials
Chandler, Arizona 85224
Principal Investigator: Nabil Dib
?
mi
from
Chandler, AZ
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Hadley Wilson
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
200 Hawthorne Ln
Charlotte, North Carolina 28204
(704) 384-4000
Principal Investigator: Jerome Williams Jr
Presbyterian Hospital At Novant Health Presbyterian Medical Center, we are welcoming a new era in...
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Bryan Wilson
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Brian Negus
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
251 E Huron St
Chicago, Illinois 60611
(312) 926-2000
Principal Investigator: Mark Ricciardi
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
Principal Investigator: Thomas Broderick
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Patrick Cambier
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Russel Raymond
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbia, Missouri 65201
Principal Investigator: Anthony Spaedy
?
mi
from
Columbia, MO
Click here to add this to my saved trials
Columbia, South Carolina 29204
Principal Investigator: Michael Foster
?
mi
from
Columbia, SC
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Vincent Pompili
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, California 94520
Principal Investigator: Gary Gershony
?
mi
from
Concord, CA
Click here to add this to my saved trials
Dallas, Texas 75226
Principal Investigator: James Choi
?
mi
from
Dallas, TX
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Kimberly Skelding
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
18101 Oakwood Blvd
Dearborn, Michigan 48124
313.593.7000
Principal Investigator: Samir Dabbous
Oakwood Hospital For more than 60 years, Oakwood Hospital - Dearborn (OH-D) has proudly served...
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Theodore Schreiber
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48236
Principal Investigator: Thomas Davis
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Doylestown, Pennsylvania 18901
Principal Investigator: Steven Guidera
?
mi
from
Doylestown, PA
Click here to add this to my saved trials
600 East Blvd
Elkhart, Indiana 46515
(574) 294-2621
Principal Investigator: Donald Westerhausen
Elkhart General Hospital For over 100 years, the highly skilled professionals of Elkhart General Hospital...
?
mi
from
Elkhart, IN
Click here to add this to my saved trials
350 Engle St
Englewood, New Jersey 07631
(201) 894-3000
Principal Investigator: Joseph De Gregorio
Englewood Hospital and Medical Center Englewood Hospital was incorporated in 1888 as a non-profit, non-sectarian...
?
mi
from
Englewood, NJ
Click here to add this to my saved trials
Everett, Washington 98201
Principal Investigator: Mahesh Mulumudi
?
mi
from
Everett, WA
Click here to add this to my saved trials
Flushing, New York 11355
Principal Investigator: Chong Park
?
mi
from
Flushing, NY
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Gurpreet Baweja
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Fremont, California 94538
Principal Investigator: Ashit Jain
?
mi
from
Fremont, CA
Click here to add this to my saved trials
743 Spring St NE
Gainesville, Georgia 30501
770-219-9000
Principal Investigator: John Marshall
Northeast Georgia Medical Center Northeast Georgia Health System (NGHS) is a not-for-profit community health system...
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
Gilbert, Arizona 85297
Principal Investigator: Nabil Dib
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
701 Grove Rd
Greenville, South Carolina 29605
(864) 455-7000
Principal Investigator: Jesse Jorgensen
Greenville Memorial Hospital Greenville Memorial Medical Campus is a regional referral center for the diagnosis...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Harrisburg, Pennsylvania 17011
Principal Investigator: William Bachinsky
?
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Harrisburg, Pennsylvania 17110
Principal Investigator: William Bachinsky
?
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Luis Tami
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Emerson Perin
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Alpesh Shah
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46237
Principal Investigator: Saeed Shaikh
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: James Hermiller
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 33207
Principal Investigator: Marc Litt
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jacksonville, Florida 32209
Principal Investigator: Theodore Bass
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kingsport, Tennessee 37660
Principal Investigator: Christopher Metzger
?
mi
from
Kingsport, TN
Click here to add this to my saved trials
La Jolla, California 92037
Principal Investigator: Richard Fortuna
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
Principal Investigator: Aaron Kaplan
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Khaled Ziada
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
1740 Nicholasville Rd
Lexington, Kentucky 40503
(859) 260-6100
Principal Investigator: Michael Jones
Central Baptist Hospital Located in Lexington, Ky., Baptist Health Lexington offers some of the most...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lincoln, Nebraska 68526
Principal Investigator: Douglas Netz
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Little Rock, Arkansas 72211
Principal Investigator: David Mego
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Liverpool, New South Wales 2170
?
mi
from
Liverpool,
Click here to add this to my saved trials
Los Angeles, California 90017
Principal Investigator: Burstein
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90066
Principal Investigator: Tobis
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Naresh Solankhi
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Louisville, Kentucky 40207
Principal Investigator: Thomas Tu
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Loveland, Colorado 80538
Principal Investigator: Anthony Doing
?
mi
from
Loveland, CO
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Ferdinand Leya
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Mesa, Arizona 85206
Principal Investigator: Alphonse Ambrosia
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
8900 N Kendall Dr
Miami, Florida 33176
(786) 596-1960
Principal Investigator: Ramon Quesada
Baptist Hospital of Miami Since 1960, Baptist Hospital of Miami has been one of the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Missoula, Montana 59802
Principal Investigator: James Maddux
?
mi
from
Missoula, MT
Click here to add this to my saved trials
Morristown, New Jersey 07960
Principal Investigator: Barry Cohen
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
Neptune, New Jersey 07754
Principal Investigator: Matthew Bach
?
mi
from
Neptune, NJ
Click here to add this to my saved trials
20 York St, N20 York St,
New Haven, Connecticut 06520
(203) 688-4242
Principal Investigator: Michael Cleman
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Patel
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Shing Wong
?
mi
from
New York, NY
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Jeffrey Moses
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
4440 West 95th Street
Oak Lawn, Illinois 60453
708.684.8000
Principal Investigator: Paul Silverman
Advocate Christ Medical Center Advocate Health Care, named among the nation
?
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Oklahoma City, Oklahoma
Principal Investigator: George Chrysant
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68124
Principal Investigator: Agarwal
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Palm Beach Gardens, Florida 33410
Principal Investigator: Augusto Villa
?
mi
from
Palm Beach Gardens, FL
Click here to add this to my saved trials
Pembroke Pines, Florida 33028
Principal Investigator: Luis Tami
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Petoskey, Michigan 49770
Principal Investigator: Louis Cannon
?
mi
from
Petoskey, MI
Click here to add this to my saved trials
Philadelphia, Pennsylvania
Principal Investigator: Gene Chang
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15212
Principal Investigator: Tony Farah
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Catalin Toma
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
9205 SW Barnes Rd
Portland, Oregon 97225
(503) 216-1234
Principal Investigator: Ethan Korngold
Providence St. Vincent Medical Center Providence St. Vincent is renowned for its many centers of...
?
mi
from
Portland, OR
Click here to add this to my saved trials
164 Summit Ave
Providence, Rhode Island 02906
(401) 793-2500
Principal Investigator: Paul Gordon
Miriam Hospital The Miriam Hospital is a private, not-for-profit hospital, with a history of providing...
?
mi
from
Providence, RI
Click here to add this to my saved trials
Raleigh, North Carolina 27607
Principal Investigator: James Zidar
?
mi
from
Raleigh, NC
Click here to add this to my saved trials